Review

Estrogen Signals through ERβ in Breast Cancer; What We Have Learned since the Discovery of the Receptor

Harika Nagandla and Christoforos Thomas *

Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX 77030, USA; hnagandla@houstonmethodist.org
* Correspondence: cthomas3@houstonmethodist.org; Tel.: +1-713-441-6451

Abstract: Estrogen receptor (ER) β (ERβ) is the second ER subtype that mediates the effects of estrogen in target tissues along with ERα that represents a validated biomarker and target for endocrine therapy in breast cancer. ERα was the only known ER subtype until 1996 when the discovery of ERβ opened a new chapter in endocrinology and prompted a thorough reevaluation of the estrogen signaling paradigm. Unlike the oncogenic ERα, ERβ has been proposed to function as a tumor suppressor in breast cancer, and extensive research is underway to uncover the full spectrum of ERβ activities and elucidate its mechanism of action. Recent studies have relied on new transgenic models to capture effects in normal and malignant breast that were not previously detected. They have also benefited from the development of highly specific synthetic ligands that are used to demonstrate distinct mechanisms of gene regulation in cancer. As a result, significant new information about the biology and clinical importance of ERβ is now available, which is the focus of discussion in the present article.

Keywords: ERβ; breast cancer; ERβ ligands; tumor progression; tumor microenvironment

1. Introduction

Estrogen receptor α (ERα) was first identified by Elwood Jensen in 1958 [1] and cloned from MCF-7 cells in 1986. ERα had long been considered as the sole mediator of estrogen signaling until the discovery of ERβ by the group of Jan-Åke Gustafsson in 1996 [2]. ERα and ERβ are encoded from different genes that reside on separate chromosomes. The ERα gene (ESR1) is located on chromosome 6q25.1 and encodes for a protein that is 595 amino acids long, whereas the ERβ gene (ESR2) locus is on chromosome 14q23.2 and gives rise to a 530 amino acid product [3]. As members of the nuclear receptor superfamily, both ER subtypes have three main functional domains: the N-terminal domain with activation function 1 (AF-1) that regulates target gene transcription independent of ligand activation, the DNA-binding domain (DBD) that facilitates binding to specific estrogen response elements (EREs) in regulatory regions of target genes, and the receptor dimerization and C-terminal ligand-binding domain (LBD) with AF-2 function. Despite the presence of common structural and functional domains, there is 95% and 59% homology in DBD and LBD between ERα and ERβ, respectively, indicating the diverse nature of ligands that bind to ER subtypes and the similarity in the mechanism of DNA interaction during the regulation of target gene expression [4]. Minor differences in LBD and low homology in AF-1 that determines the interactions with co-regulators point to a distinct mechanism of action by the ER subtypes in target tissues.

Because of the different function of ER subtypes, the nature of estrogen response in target tissues primarily depends on the availability of the receptor subtype and the presence of co-regulators and partner transcription factors that control the transcriptional activity. ERα is mainly expressed in the mammary gland, uterus, thecal cells in the ovary, bone, male reproductive organs (testes and epididymis), prostate stroma, liver, and adipose tissue.
ERβ, on the hand, is predominant in granulosa cells of the ovary, the prostatic epithelium, bladder, colon, bone, lung, breast and adipose tissue as well as in the central nervous, cardiovascular and immune system [5–8].

Our knowledge about the biology of ERs has primarily been derived from their study in the reproductive system, mammary gland, and in breast cancer [9]. It is now well accepted that increased signaling through ERα is essential for the growth of the mammary gland during development and pregnancy but has oncogenic properties in breast cancer. About 70% of breast cancers overexpress ERα, indicating its importance as a molecular target as well as in prognosis of the disease. The induction of ERα signaling in luminal tumors has long been the focus of endocrine therapy, including the ERα antagonist tamoxifen that has represented the gold standard for treatment of ERα-positive breast cancer for over five decades. On the other hand, owing to challenges in detection due to decreased protein expression, the use of non-specific antibodies, and the contribution of alternatively spliced and differentially expressed isoforms to the immunohistochemical signal, initial reports of ERβ action and clinical importance in breast cancer were conflicting. Over two decades of extensive research using preclinical models and human specimens has reinvigorated interest in ERβ by uncovering effects that link the expression and function of the receptor to the biology of the disease. While ERβ is expressed in epithelial, myoepithelial and stromal cells of breast tissue during development and in adulthood, its levels have been reported to decline in breast cancer [10–14] due to oncogenic signaling that primarily represses the activity of the promoter of the ERβ gene [14,15]. The decreased expression in malignant breast together with the anti-proliferative and anti-invasive effects of the receptor upon upregulation in cancer cells represents the strongest indication of a tumor suppressor function.

In this review we first discuss what we have learned about the biology of ERβ from the complete and tissue-specific knockout mouse models. We also present information from studies looking at the role of the receptor in cell proliferation, invasion and metastasis. Since breast cancer is one of the most well-studied disease models for ERβ function, we additionally focus on the involvement of the receptor in the prevention and treatment of refractory disease. Considering the potential of targeting ERβ in breast cancer, we also discuss recent advancements in some of the most commonly used ERβ synthetic agonists. Finally, given the well-documented implication of tumor immunity on cancer progression, we explore the theme of estrogen receptor action in the tumor microenvironment.

2. The Phenotypes of ERβ Knockout Mouse Models

Several mouse models with constitutive deletion of ERβ in all tissues have been generated to date [16–19]. Earlier models were developed involving either deletion of exon 3 by the Cre-LoxP system [17,19] or disruption of the gene with the insertion of a neo cassette into exon 3 of the receptor in embryonic stem cells by homologous recombination [16]. The key finding that was consistent throughout the analysis of the three original knockout models was the severe disruption of ovulation in the absence of ERβ. The phenotyping of the latest mouse model with the crispr-cas9-mediated knockout of ERβ reports a tumor suppressor function in the ventral prostate and mammary epithelium, where the loss of the receptor leads to increased activity of the androgen receptor (AR) and ERα, respectively [18]. Although the expression of genes that are involved in the promotion of prostate cancer increased upon ERβ deletion, loss of the receptor alone did not lead to the development of prostate cancer [16]. Instead, ventral prostate epithelial hyperplasia and intraductal cancer-like lesions were observed in the absence of ERβ, which is consistent with the significantly higher number of ki67- and p63-positive cells in the same tissue of six-month-old ERβ knockout mice [18]. Of note, epithelial hyperplasia declined in the prostate of the same mice by the time they reached 18 months of age, linking this process to the physiology of the gland and the activity of the receptor in earlier stages of adult life [18].

Deletion of ERβ in mice was also shown to reduce the differentiation of mammary gland epithelium and decrease the levels of the adhesion molecules E-cadherin, connexin 32,
occludin and integrin α [16]. The mammary gland of ERβ knockout mice had increased expression of ERα, PR and ki67 as well as more invasive epithelium with a higher expression of matrix metalloproteinases (MMPs) [18]. These results point to a key role for ERβ in controlling growth and promote the differentiation of prostate and mammary gland tissues in mice.

3. Effects of Tissue-Specific Deletion of ERβ

Several tissue-specific ERβ knockout mouse models have been developed and analyzed to characterize functions of the receptor on certain mouse organs. Muscle-specific deletion of ERβ led to a decrease in muscle mass and strength in female mice only [20]. Although ERβ is expressed in both male and female mice, genetic ablation of ERβ in muscle stem cells (satellite cells) caused impaired muscle regeneration following injury specifically in young female mice, pointing to the importance of ERβ in post-natal muscle growth [20]. On the other hand, deletion of ERβ in intestinal epithelial cells revealed a protective role of the receptor in colitis-induced adenomas by countering TNFα- and NFκB-mediated inflammation [21]. Knockout of ERβ induced more colorectal tumors in male mice, while female mice developed significantly larger tumors in the absence of the receptor [21]. Intestine-specific depletion of ERβ was also found to limit diversity in the gut microbiome during chemically induced colitis leading to colorectal cancer (CRC) [22]. In another study that was designed to test the selective activation of ERα or ERβ with specific ligands on the oncogenic activity of high fat diet (HFD), activation of ERβ elicited anti-inflammatory effects in the colon, as manifested by significantly reduced macrophage infiltration in both male and female mice [23], and protected against HFD-induced proliferation of colonic epithelial cells [23].

In addition to the intestine, effects of ERβ were investigated in mouse mammary gland using tissue-specific knockout models. Effective synergism between ERβ and the p53 tumor suppressor function was noted in breast cancer upon conditional deletion of both genes in mammary epithelial cells [24]. While knockout of ERβ alone did not give rise to mammary tumors, loss of the receptor in p53-defective tissues significantly shortened tumor latency compared with the conditional deletion of p53 alone [24]. Because ERβ has been reported to interact with both wild-type and mutant p53 enhancing the tumor suppressor function of the protein, the observed synergistic anti-tumor activity was linked to the function of the receptor in the developing mammary gland. During this period of extensive growth with an anticipated reduced capacity for genome surveillance due to p53 inactivation, loss of ERβ signaling can lead to the induction of aberrant cell proliferation and impaired differentiation and DNA repair to malignant transformation [25].

4. Post-Translational Modifications of ERβ

Serine residue (S) at positions 75, 87 and 105 in human ERβ were found to be targets of ERK1/2 and p38 kinases. S105 of endogenous ERβ was shown to undergo phosphorylation in MDA-MB-231 and BT-474 cells, enhancing the ability of the receptor to inhibit cell migration and invasion in vitro without affecting cell growth and cell cycle progression [26]. Consistent with the in vitro anti-tumor activity, phosphorylation of ERβ at S105 has been associated with a favorable prognosis in breast cancer [27]. On the other hand, the highly conserved MAPK target site S87 of ERβ was found to undergo phosphorylation by the stromal cell-derived growth factor 1 (SDF-1 or CXCL12) that enhances the occupancy of ERβ at EREs and AP1 sites, even in presence of tamoxifen [28].

Phosphorylation of ERβ at serine residues at positions 106 and 124 by MAP kinase has been shown to increase the interaction of ERβ with the co-activator SRC-1. When MAP kinase is activated by Ras, EGF or IGF-1, it stimulates the phosphorylation of serines in AF-1 of ERβ leading to an increased interaction with SRC-1 and ligand-independent activation of the receptor [29]. In addition to the human receptor, S16 in mouse ERβ was shown to be either phosphorylated or modified through O-glycosylation. Phosphorylation
of S16 accelerated the degradation of mouse ERβ, whereas O-glycosylation of the same residue increased the stability of the receptor and its transcripational activity [30,31].

Interestingly, the phosphorylation status of tyrosine 36 (Y36) of ERβ was found to be under the diametrically opposite control of c-ABL tyrosine kinase and EYA2 phosphatase. Phosphorylation of Y36 that is increased by the agonists 17β-estradiol, diarylpropionitrile (DPN) and S-equol is required for recruitment of ERβ co-activators to the promoters of target genes and causes inhibition of ERα-induced cancer cell growth in vitro and in xenografts [32,33]. In addition to regulating interaction with co-activators, the same phosphorylation has been reported to increase the turnover of the receptor by decreasing protein stability since mutant ERβ (Y36F), where tyrosine was replaced with phenylalanine, was more resistant to ubiquitin-mediated protein degradation [32]. Lastly, another residue that was also found to undergo phosphorylation is S6. This phosphorylation is necessary for sumoylation of ERβ at Lysine 4 that can be enhanced by constitutively active MAP/ERK kinases [34]. Sumoylation-deficient ERβ mutants displayed greater transcriptional activity in response to estrogen treatment, indicating the negative effect of sumoylation on the activity of the receptor, considering the function of Lysine-4 of ERβ as a suitable site for ubiquitination [34].

5. ERβ and Breast Cancer Cell Proliferation

Early studies using Taqman-based qPCR analysis showed that in contrast to ERα, which is upregulated in luminal tumors, ERβ mRNA levels were lower in breast tumor samples compared to normal breast tissue [11]. Consistent with the mRNA levels, quantitative immunohistochemistry clearly demonstrated higher expression of ERβ in benign breast with a sharp decline in breast carcinoma in situ (CIS) [35]. In line with the higher levels of ERβ in differentiated epithelium, the expression of the receptor exhibited a strong inverse correlation with that of the proliferation marker ki67 in ductal carcinoma in situ [35].

Despite the decrease of ERβ expression in malignant breast, a significant number of specimens from patients with hormone receptor-positive breast cancer were reported positive for ERβ. Expression of the receptor was strongly associated with pre-menopausal status and markers of less aggressive phenotypes, including axillary lymph node negativity and lower S phase fractions [36]. At the preclinical level, introducing ERβ in ERα-positive MCF-7 cells inhibited their proliferation in vitro and in xenografts in vivo. Expression of ERβ also caused G2 cell cycle arrest by repressing the transcription of cyclin D1, cyclin A and c-myc [37], and similar effects were observed in another luminal breast cancer cell line, the T47D cells [38]. ERβ was also found to counter Akt signaling by downregulating the upstream HER2/HER3 receptor dimer and upregulating the tumor suppressor PTEN that is known to inhibit Akt signaling in breast cancer cells [39].

ERβ can regulate the expression of oncogenes and tumor suppressors in luminal breast cancer cells in an ERα-dependent or independent fashion. ERα and ERβ can form heterodimers that control the recruitment of the co-activator SRC-1 [40–42]. ERα/ERβ heterodimers are less efficient than ERα homodimers in transactivating target genes, implying an inhibitory effect of ERβ in the transcriptional activity of ERα. In support of this mechanism of action, a microarray-based transcriptomic analysis in T47D cells revealed inhibition of ERα target gene expression upon induction of ERβ expression. Genes that were induced by ERα and repressed by ERβ were involved in cell proliferation, a finding that was also supported by in vitro cell proliferation assays [43]. Consistent with these studies and other previous findings [37], over-expression of ERβ in MCF-7 cells led to a marked decrease of estrogen-induced cell proliferation, and the analysis of binding sites in ERβ-transfected cells identified gene expression signatures that correlate with the inhibition of cell proliferation [44]. In agreement with the in vitro studies, less orthotopic ERβ-expressing T47D tumors were developed in SCID mice compared to xenografts that did not express the receptor [45]. Tumors expressing ERβ also had fewer blood vessels and reduced expression of proangiogenic factors [45]. The anti-proliferative effects of ERβ were primarily observed in ERα-positive breast cancer cells, suggesting that this specific
function may result from interference with the pro-proliferative activity of ERα. This interaction in cells with variable expression of artificially introduced ERβ may also explain the publication of inconsistent data on cell proliferation in ERα-positive cells [46].

6. ERβ in Cancer Cell Invasion and Metastasis

In one of the earliest studies, the tumor repressive role of ERβ in prostate cancer was demonstrated through its adenovirus-driven expression in ERα-negative DU145 prostate cancer cells that caused a significant reduction of invasion in a matrigel-coated transwell assay [47]. Similar to DU145 cells, treatment of ERβ-transfected PC3 prostate cancer cells with agonists decreased cell migration and induced the expression of INPP4B, a repressor of Akt signaling [48]. In addition, overexpression of ERβ also reduced cell viability, migration, and inflammation and enhanced apoptosis in PC-3 and DU145 cells by suppressing lipopolysaccharide (LPS)-induced activation of NFκB that represents another driver of prostate cancer progression and mediator of inflammation [49].

Unlike the documented tumor suppressor role of ERβ in breast, prostate, ovarian, renal and thyroid cancer [50], reports of ERβ action in lung cancer have been controversial [51], with several groups supporting an oncogenic function of the receptor [52–58]. A recent study in non-small-cell lung cancer (NSCLC) cells showed that ERβ promotes invasion by directly binding to and inducing the expression of TMX4 circular RNA, which, through the inhibition of miR-622, leads to upregulation of the G protein-coupled receptor (GPCR) CXCR4 that promotes metastasis in several types of cancer [53]. Consistent with this function, knockdown of ERβ in lung cancer cells led to reduced vasculogenic mimicry and invasion, whereas overexpression of ERβ had the opposite effect [59]. ERβ also promoted cell invasion by directly binding to the regulatory region of IncRNA MALAT1 and increasing its expression, which, in turn, downregulates miR-145-5p and upregulates the oncogenic factor NEDD9 [59]. In line with the preclinical data, female patients with ERβ-positive NSCLC tumors had worse 5-year survival compared to those without ERβ expression [59]. Although an oncogenic function of ERβ in the lung should not be excluded and may be associated with the biology of the tissue, the pro-invasive effects in cancer cells following upregulation of the receptor need to be considered with extra caution and further validated to exclude non-physiological activation by the artificial expression.

In contrast to lung cancer, there is consensus regarding the anti-invasive and anti-metastatic role of ERβ in breast cancer. Claudin-6 (CLDN6), a tight junction protein and tumor suppressor, was found to be a direct target of ERβ in breast cancer cells [60]. Treatment of MDA-MB-231 and ERβ-overexpressing SK-BR-3 breast cancer cells with the ERβ-specific agonist DPN caused autophagy through CLDN6-mediated upregulation of the key mediator of autophagy beclin-1 (Figure 1). Overexpression of CLDN6 in MDA-MB-231 cells also led to reduced lung and liver metastasis in mice [60]. Upregulation of ERβ in TNBC (triple negative breast cancer) MDA-MB-231 and Hs578T cell lines induced the expression of the epithelial marker E-cadherin and suppressed cell migration and invasion in vitro as well as in zebrafish embryos [61]. ERβ was found to promote ubiquitination and degradation of EGFR along with induction of members of the miR200 family leading to subsequent inhibition of the transcriptional repressors of E-cadherin SIP1 and ZEB1 (Figure 1). Consistent with the association in cancer cells, ERβ protein levels positively correlated with those of E-cadherin in clinical patient samples [61]. ERβ was also found to transcriptionally repress EGFR, thereby indirectly downregulating IMP3 to counter invasion and migration in TNBC [62]. G protein-coupled estrogen receptor 1 (GPER) is a membrane-bound estrogen receptor that has been shown, like other GPCRs, to transactivate EGFR [63]. GPER expression positively correlates with disease progression in breast cancer patients [64]. Since ERβ has already been shown to transcriptionally downregulate another G protein-coupled receptor—GPR141—to inhibit actin-based migration in inflammatory breast cancer [65], there is a possibility of functional crosstalk between ERβ and GPER or other GPCRs, where ERβ might oppose EGFR signaling by inhibiting the expression and activity of GPER. In addition to inhibiting EGFR, ERβ was shown to reduce invasion in
TNBC cells by directly interacting with and blocking transcription by the oncogenic mutant p53 that exists in about 80% of TNBCs (Figure 1) [25]. Similarly, ligand-mediated activation of ERβ in TNBC cells resulted in their decreased invasion and in vivo lung colonization through upregulation of several members of the family of cystatins via direct binding of the receptor to their regulatory elements (Figure 1) [66]. The importance of cystatins for TNBC metastasis was verified by their ability to decrease the invasiveness of TNBC cells by repressing TGFβ signaling and their association with longer recurrence-free survival (RFS) in patients (Figure 1) [66]. In addition to TNBC, ERβ was found to decrease the invasiveness of inflammatory breast cancer (IBC) cells by downregulating GPR141 and the guanine nucleotide exchange factor (GEF)-interacting protein ELMO1 that activate the mediator of IBC metastasis RhoC [65]. In contrast to ERβ, a few studies provided conflicting evidence about the role of ERα in the invasiveness and metastatic potential of breast cancer cells. Initially, silencing of ERα has been shown to cause epithelial to mesenchymal transition (EMT) in ERα-positive breast cancer cells [67]. Subsequently, ERα has been reported to promote breast cancer cell migration and invasion by actin cytoskeletal remodeling through focal adhesion kinase (FAK) and N-WASP [68] and through Rho-associated kinase 2 (ROCK-2) [69].

![Figure 1](image_url)  
**Figure 1.** Flow chart depicting effects of ERβ on EMT, cell migration and metastasis in breast cancer. Cystatins 1, 2, 4 and 5 are direct targets of ERβ in triple negative breast cancer (TNBC) cells. Expression of ERβ in TNBC cells followed by agonist activation inhibits metastasis in vivo by inducing the expression of cystatins that downregulate TGFβ signaling. Beclin-1, a key regulator of autophagy is upregulated by Claudin-6, a direct target of ERβ in breast cancer. Claudin-6 inhibits breast cancer cell migration and invasion. ERβ represses transcription of the activators of the cytoskeleton remodeler RhoC, ELMO1 and GRP141, by directly binding to their regulatory regions, thereby preventing RhoC activation and actin-based cell migration. Approximately 80% of TNBCs harbor oncogenic mutations of p53. ERβ directly interacts with mutant p53 and inhibits its pro-metastatic signaling. ERβ also inhibits epithelial–mesenchymal transition (EMT) by inducing EGFR degradation that results in upregulation of the epithelial markers miR-200a-b-429 and E-cadherin.

7. **ERβ in TNBC**

TNBC is marked by the absence of the receptors ERα, PR and HER2 that have been validated as oncogenic drivers in other subtypes of breast cancer. Although TNBC accounts for approximately 15% of total breast cancers, it is responsible for the majority of breast cancer-associated deaths [70]. This is, in part, due to the high propensity of TNBC tumors to develop metastasis, the high frequency of resistance to standard chemotherapy and the lack of effective targeted therapy.
Different isoforms of ERβ have been associated with clinical outcomes in TNBC. These include the full length ERβ (also known as ERβ1) that is composed of 530 amino acids and is the only isoform that forms homodimers and heterodimers and bind ligands [71]. On the other hand, the variants ERβ2, 3, 4 and 5 that result from alternative splicing of the last coding exon form heterodimers with ERβ1 and have an impaired ability to bind ligands (Figure 2) [71]. The expression of ERβ1 has been reported in about 18–27% of TNBC cases, and earlier studies indicated the importance of the receptor as an independent predictor of a favorable prognosis [72–76]. As per a recent report from Katzenellenbogen lab, ERβ2 and ERβ5 are the most abundant isoforms in TNBC cell lines and tumors, whereas ERβ1 is barely detectable. In contrast to ERβ1, the variants 2 and 5 were found to elicit an oncogenic function since knockdown in TNBC cells decreased proliferation, migration and invasion, whereas their overexpression had the opposite effect on these specific cellular phenotypes [71,77]. At the mechanistic level, overexpression of ERβ1 and treatment with specific ligands increased the protein levels of the epithelial and anti-invasive marker E-cadherin [61,62]. Upregulation of ERβ1 also reduced the expression of the oncogenic survivin (BIRC5), similar to the depletion of ERβ2 and ERβ5, suggesting opposing effects of ERβ isoforms on gene regulation [77]. The oncogenic activity of the variants is in agreement with previous findings, suggesting an association of ERβ2 with poor prognosis in hormone receptor-negative breast cancer [73,77]. Similar to TNBC, in high-grade serous ovarian cancer, where more than 95% of the tumors harbor p53 mutations, ERβ2 was found to partner with mutant p53 to increase the transcription of FOXM1, leading to enhanced proliferation and therapy resistance [78]. The transcriptional activation of mutant p53 by ERβ2 represents another example of the opposite function of the variants in cancer considering the previously reported inhibitory interaction of ERβ1 with mutant p53 in TNBC [25].

In addition to mutant p53, the full length ERβ has been shown to inhibit the function of other known drivers of TNBC. Expression of ERβ1 has been reported to induce apoptosis and reduce the proliferation and metastatic potential of androgen receptor (AR)-positive TNBC cells [76]. Similar, upregulation of ERβ1 increased the sensitivity of the same cells to the AR inhibitor enzalutamide [79]. ERβ1 decreased the activity of AR by forming heterodimers and inhibiting PI3K/Akt signaling. The same variant was also shown to inhibit proliferation and migration of TNBC cells by forming a co-repressor complex with PRC2/EZH2 to repress the transcription of p65/RelA and downregulate the NFkB pathway [75,76]. Similar to upregulation, treatment with the ERβ agonist liquiritigenin inhibited cell proliferation and increased the sensitivity of TNBC cells to doxorubicin [80]. As with the cell proliferation, treatment with ERβ agonists greatly mitigated the invasion of TNBC cells when they were grown alone [81] and during their co-culture with MG63 osteoblasts [82]. Lastly, ERβ1 was also found in the same cells to downregulate the oncogenic pathway of cholesterol biosynthesis by binding to the promoter of SREBP1 [76]. The opposing effects of the variants together with their variable expression in tumors may have accounted for the initial controversy surrounding the role of ERβ in TNBC [83,84]. Recent findings, however, have improved our understanding about the exact actions of the receptor and its clinical importance for the disease [85,86].
isoform

Figure 2. Structural and functional domains of estrogen receptor β. Domains are shown for both the full length ERβ (also called ERβ1) and its isoforms ERβ2-5. Numbers indicate amino acid length of individual domains and the full length proteins. All ERβ isoforms are identical until the hinge region, where they begin diverging from the C-terminal of the ligand-binding domain (LBD). The ligand-independent transactivation function (AF-1) resides in the N-terminus of the receptor and serves as an interaction site for regulatory factors. The DNA-binding domain (DBD) recognizes estrogen response elements (ERE) in regulatory regions of target genes, whereas the hinge region harbors a nuclear localization signal (NLS). The LBD consists of the ligand-binding transactivation function (AF-2) and provides an interface for receptor dimerization and co-activator binding.

8. Synthetic Ligands and ERβ Activity

The nature of the estrogenic ligand effect largely depends on the conformation of the ligand-binding domain (LBD) of ER subtypes. ERα and ERβ share a medium homology of 59% in the primary protein sequence of LBD [87]. The LBD in both isoforms has important features such as the ligand-dependent transcription activation function (AF2), a homo- or hetero-dimerization interface and an interaction surface for co-regulators [88]. The LBDs of ERα and ERβ have a similar globular structure and consist of 11 α-helices organized as a three-layered sandwich structure with helices 4, 5, 6, 8 and 9 flanked on one side by helices 1 and 3, and by helices 7, 10 and 11 on the other [88,89]. 22 hydrophobic residues line the ligand-binding cavity in ERs and interact with the ligand [90]. The orientation of helix 12 with respect to the ligand-binding pocket determines whether a ligand serves as an agonist or antagonist. In an agonist-bound conformation, helix 12 is positioned at the entrance of a ligand-binding cavity and serves as an interaction surface for nuclear receptor co-activators [91]. Antagonists alter helix 12 positioning in a manner that blocks recruitment of co-activators [91]. The ligand-binding cavity of ERβ is smaller in size and narrower compared to that of ERα. ERβ also differs from ERα in two residues out of the 22 that form the ligand-binding cavity. Leu384 and Met421 in ERα are replaced by Met336 and Ile373, respectively, in ERβ [87,89].

8.1. Raloxifene

Raloxifene binds both ERα and ERβ with high affinity (Figure 3) [92]. It acts as an ERα antagonist in the mammary gland and uterus and as an agonist in bone and the liver [93]. In a clinical trial with more than 10,000 post-menopausal women, raloxifene significantly reduced the risk of invasive breast cancer, had no effects on outcomes that were
associated with coronary heart disease, but increased the risk of fatal stroke [94] and venous thromboembolism [94,95]. This ER ligand was also found to increase bone mineral density and lower the levels of total cholesterol and LDL in post-menopausal women [96] and, hence, it was approved for the treatment of osteoporosis in post-menopausal women in 2007. In addition to ERα, recent preclinical studies showed that the nano formulation of raloxifene inhibited TNBC tumor growth in vitro and in vivo, partially through regulating the activity of ERβ [97]. Similar to TNBC, the drug was also shown to inhibit migration of hepatocellular cancer cells through ERβ-mediated inhibition of the Akt signaling pathway [98]. Raloxifene was further found to inhibit the progression of pancreatic ductal adenocarcinoma (PDAC) in an orthotopic xenograft model through ERβ [99]. Moreover, it mitigated metastasis and elicited tumor suppressive effects in AR-negative and castration-resistant prostate cancer (CRPC) [100]. These findings suggest a role for ERβ in repurposing ER ligands for use in treatment of ERα-negative malignancies.

**Figure 3.** Chemical structure of synthetic ligands of estrogen receptors tamoxifen, raloxifene and LY500307.

### 8.2. Tamoxifen

Tamoxifen acts as an ERα antagonist in breast tissue and an agonist in the uterus, bone, and the liver (Figure 3) [101,102]. Tamoxifen was first approved by the FDA for the treatment of ERα-positive breast cancer in 1977 and later as an adjuvant treatment for primary breast cancer [103]. Application of tamoxifen therapy significantly benefited patients with the disease since it reduced breast cancer-associated mortality by a third [104]. Although ERα appears as the primary mediator of the clinical effects of the drug, new evidence suggests that tamoxifen can also affect breast cancer through ERβ. Initially, low ERβ protein levels in ERα-positive tumors were reported to predict resistance to tamoxifen [105,106], and treatment of breast cancer cells with ERβ-selective agonists enhanced the growth-inhibitory effects of tamoxifen [107-109]. Similarly, ERβ sensitized tamoxifen-resistant MCF-7 cells to endoplasmic reticulum (ER) stress apoptosis by downregulating the unfolded protein response (UPR) [109]. Tamoxifen was also shown to inhibit mutant p53-dependent oncogenic gene expression in ERβ-expressing but not in control MDA-MB-231 TNBC cells [25]. On the other hand, the ligand was found to engage mitochondrial ERβ, both as agonist and antagonist, thereby modulating the levels of manganese superoxide dismutase (MnSoD) and contributing to tamoxifen resistance [110]. In addition to breast cancer, targeting ERβ with tamoxifen in diffuse large B-cell lymphoma (DLBCL) reduced cell viability in vitro, an effect that was significantly mitigated with knockdown of ERβ [111] and corroborated in a xenograft lymphoma model [111].

### 8.3. LY500307

Several studies have reported the anti-tumor activity of the ERβ-selective agonist LY500307 since its development by researchers at Eli Lilly in 2012 (Figure 3). Treatment with LY500307 caused suppression of TNBC and melanoma lung colonization by inducing recruitment of neutrophils to the metastatic site (Figure 4A) [112]. The recruitment of
neutrophils was associated with the expression and secretion of IL-1β from cancer cells, and the involvement of this specific cytokine was verified by the absence of anti-metastatic effects of LY500307 in IL-1β knockout mice [112]. Treatment with LY500307 also improved the efficacy of the PD-1 antibody in in vivo models of TNBC and colorectal cancer [113]. In addition to regulating neutrophils, LY500307 reduced the recruitment of CSF-1 receptor-positive myeloid-derived suppressor cells (MDSC) to the tumor microenvironment while also increasing CD8+ cytotoxic T cells by decreasing the production of CSF-1 by tumor cells (Figure 4D) [113]. Beyond TNBC, activating tumor-endogenous ERβ by treating mice bearing orthotopically implanted inflammatory breast cancer tumors with LY500307 led to reduced lung metastasis (Figure 4B) [65]. In addition to IBC, ERβ was also found to be enriched in ovarian cancer stem cells (OVSC), and treatment with LY500307 reduced their stemness and induced apoptosis [114]. Treatment with LY500307 also significantly impaired the tumor-initiating potential of OVSCs in orthotopically implanted xenograft models [114]. Similarly, glioblastomas (GBM) express ERβ, and treatment of GBM cells with this selective agonist reduced proliferation and enhanced apoptosis in vitro (Figure 4C). More importantly, the ligand improved the survival of GBM tumor-bearing mice and inhibited in vivo tumor growth [115]. In an attempt to potentiate ERβ signaling after treatment with LY500307 and driven by the observed increased acetylation of the ERβ promoter, glioblastoma cells were incubated with HDAC inhibitors. HDAC inhibitors did indeed increase the expression of ERβ and upregulated its target genes, and the combination of these inhibitors with LY500307 enhanced the survival of mice with orthotopic GBM tumors [116]. Similar results were observed in melanoma cell lines, where treatment with LY500307 reduced cell proliferation, increased apoptosis, decreased cell migration and partially reversed EMT [117]. Despite the enthusiasm generated as a result of the use of the compound in preclinical cancer models and its demonstrated in vivo anti-tumor activity, LY500307 failed to show clinical efficacy in clinical trials for other conditions, including men with benign prostatic hyperplasia (BPH) [118] and patients with cognitive impairment associated with schizophrenia [119].
Despite the documented association of estrogen signaling with the function of the immune system in various pathophysiological conditions, the role of estrogen receptors in regulating tumor immunity still remains elusive, partially due to the lack of appropriate syngeneic and transgenic immunocompetent tumor models. Only a few studies have explored the function of ERβ in regulating tumor immunity still remains elusive, partially due to the lack of appropriate syngeneic and transgenic immunocompetent tumor models. Only a few studies have explored the function of ERβ in regulating tumor immunity still remains elusive, partially due to the lack of appropriate syngeneic and transgenic immunocompetent tumor models. Only a few studies have explored the function of ERβ in regulating tumor immunity still remains elusive, partially due to the lack of appropriate syngeneic and transgenic immunocompetent tumor models.

9. ERβ and the Tumor Microenvironment

Despite the documented association of estrogen signaling with the function of the immune system in various pathophysiological conditions, the role of estrogen receptors in regulating tumor immunity still remains elusive, partially due to the lack of appropriate syngeneic and transgenic immunocompetent tumor models. Only a few studies have explored the function of ERβ in the tumor microenvironment and how this impacts cancer progression and metastasis. One of these studies has focused on bladder cancer, where ERβ has been detected as the predominant ER subtype in both cell lines and tumor samples [120]. Higher expression of ERβ has been reported in metastatic tissue compared to benign urothelium and is strongly correlated with more aggressive phenotypes [121]. This correlation has been explained by the recruitment of ERβ-expressing mast cells [122] and CD4+ T cells [123] in bladder cancer and by the association of mast and CD4+ T cells in the tumor microenvironment with enhanced invasiveness of bladder cancer cells. The effect of ERβ was verified by treatment with the ERβ antagonist PHTPP or ERβ shRNA that abrogated the increased invasiveness of bladder cancer cells [122].

In addition to bladder cancer, estrogen signaling has been linked to the microenvironment of breast cancer. However, most of the evidence supporting this association has been
derived from the study of ERα. It is well accepted that immune cell infiltrates in the breast tumor microenvironment are altered based on ERα status [124]. For example, numerous studies have shown an association between high eosinophil count in peripheral blood and survival benefit in patients with ERα-negative breast cancer [125–127]. On the other hand, ERα is known to mediate the immune-suppressive effects of 17β-estradiol that are, in part, dependent on FoxP3-positive regulatory T cells (Tregs) [128]. In addition to recruitment, treatment with 17β-estradiol increased the activity of Tregs by inducing their intracellular expression of PD-1. The involvement of ERα was confirmed through the analysis of ERα knockout mice where the intracellular expression of PD-1 and Treg-mediated immune suppression were reduced [129].

The involvement of Tregs in estrogen-associated immunoregulation has also been observed in other conditions. These include the auto-immune disorders such as inflammatory bowel disease (IBD), where ERβ as the predominant ER subtype in intestinal mucosa [130] was shown to elicit potent anti-inflammatory effects [130–134]. The population of ERβ+CD4+ T cells was significantly lower in experimentally induced IBD and was associated with increased disease severity [135,136]. Treatment with ERβ-specific agonists countered inflammation in IBD by inducing differentiation of naïve T cells to Tregs and inhibiting pro-inflammatory T cell responses [135].

In addition to Tregs, ERβ has been shown to affect breast cancer by regulating other components of the immune system. The selective ERβ agonist LY500307 has been reported to suppress metastasis of TNBC by inducing tumor cell expression and secretion of IL-1β, resulting in subsequent recruitment of neutrophils to the metastatic site [112]. The same ligand also increased the sensitivity of TNBC tumors to PD-1-based immunotherapy [113]. In addition to neutrophils, LY500307 inhibited the expression of CSF-1 in tumor cells, leading to reduced recruitment of myeloid-derived suppressor cells (MDSC) and an increase in CD8+ cytotoxic T cells in the tumor microenvironment [113]. The role of ERβ signaling in the cells of the tumor microenvironment was evaluated by generating mice with a mutated mouse ERβ, where the tyrosine 55 residue that is equivalent to Y36 in human ERβ and essential for maintaining an active receptor through phosphorylation was replaced with a phenylalanine. Mice with whole body homozygous mutated ERβ unable to undergo phosphorylation exhibited significantly faster growth of orthotopically implanted syngeneic mammary and melanoma tumors [137]. Replacing bone marrow of wild-type mice with bone marrow from ERβ mutant mice led to fewer tumor-infiltrating CD8+ and CD4+ T cells compared to the control mice, indicating the impaired ability of host immune cells to control tumor growth in the absence of ERβ signaling. Indeed, CD8+ T cells in mice with a mutated ERβ phosphotyrosine switch (Y55) produced lower amounts of anti-tumor cytokines [137].

10. Concluding Remarks

Although initial reports of ERβ action were conflicting, generating skepticism about the role and clinical importance of the receptor, extensive research in the last decade has increased our confidence for a tumor suppressor function in breast cancer. In addition to the direct effects of the receptor on tumor cells, recent studies have revealed entirely new courses of action through regulation of the tumor microenvironment. Activation of ERβ in tumor cells is now known to alter tumor immunity through the secretion of immunomodulatory cytokines [112,113]. In addition to tumor epithelial cells, ERβ is expressed in various cell types including endothelial cells, fibroblasts and tumor-infiltrating lymphocytes [138–141]. This underscores the importance of determining the ability of ERβ to signal from the tumor microenvironment to regulate tumor development and metastasis and the capacity of ligands to enhance ERβ signaling in these cells and achieve favorable clinical outcomes by potentiating the anti-tumor activity of the host immune system. As ERβ has been reported to act as a tumor suppressor in various malignancies including breast, prostate, colorectal, ovarian and glioblastoma [50], further research to corroborate this function and define the mechanism of action will be essential in order to determine the
value of the receptor as biomarker and therapeutic target and its utility in new approaches to combat the resistant and metastatic states of these diseases.

**Funding:** This work was supported by the grants R01CA237200 and R21CA267386 from NCI (to C. Thomas).

**Conflicts of Interest:** The authors declare no potential conflicts of interest.

**References**


Receptors 2024, 3


41. Pace, P.; Taylor, J.; Suntharalingam, S.; Coombes, R.C.; Ali, S. Human estrogen receptor β binds DNA in a manner similar to and dimerizes with estrogen receptor α. J. Biol. Chem. 1997, 272, 25832–25838. [CrossRef]


59. Yu, W.; Ding, J.; He, M.; Chen, Y.; Wang, R.; Han, Z.; Xing, E.Z.; Zhang, C.; Yeh, S. Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the IncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer. Oncogene 2019, 38, 1225–1238. [CrossRef] [PubMed]


75. Aspros, K.G.; Carter, J.M.; Hoskin, T.L.; Suman, V.J.; Subramaniam, M.; Emch, M.J.; Ye, Z.; Sun, Z.; Sinnwell, J.P.; Thompson, K. Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFkappaB/p65 signaling in triple negative breast cancer. NPJ Breast Cancer 2022, 8, 20. [CrossRef]


90. Pike, A.C.; Brzozowski, A.M.; Hubbard, R.E.; Bonn, T.; Thorsell, A.-G.; Engström, O.; Ljunggren, J.; Gustafsson, J.-Å.; Carlquist, M. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999, 18, 4608–4618. [CrossRef]


100. Palmer, H.; Nimick, M.; Mazumder, A.; Taurin, S.; Rana, Z.; Rosen gren, R. Raloxifene Suppresses Tumor Growth and Metastasis in an Orthotopic Model of Castration-Resistant Prostate Cancer. *Biomedicines* 2022, 10, 853. [CrossRef]


114. Rajapaksa, G.; Nikols, F.; Bado, I.; Clarke, R.; Gustafsson, J.-Ä.; Thomas, C. ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway. *Oncogene* 2015, 34, 4130-4141. [CrossRef] [PubMed]


Receptors 2024, 3


126. Ghebeh, H.; Elshenawy, M.A.; AlSayed, A.D.; Al-Tweigeri, T. Peripheral blood eosinophil count is associated with response to chemoinmunotherapy in metastatic triple-negative breast cancer. Immunotherapy 2022, 14, 189–199. [CrossRef] [PubMed]


138. Sapino, A.; Bosco, M.; Cassoni, P.; Castellano, I.; Arisio, R.; Cserni, G.; Dei Tos, A.P.; Fortunati, N.; Catalano, M.G.; Bussolati, G. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Mod. Pathol. 2006, 19, 599–606. [CrossRef] [PubMed]


**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.